For the pharmaceutical industry, the proposed tax reform might be spelled this way: G-I-F-T.
After years of grousing about the tax code, drug makers stand to benefit substantially from the changes the Trump administration is seeking. In fact, to a great extent, the plan that the White House is proposing appears to check off a few key items on an industry wish list, according to one tax expert.
“It looks very positive for the pharmaceutical companies,” said Robert Willens, an independent tax adviser who tracks corporate tax maneuvers.
About the Author Reprints
